TY - JOUR
T1 - A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent Transcription
AU - Yokoyama, Akihiko
AU - Lin, Min
AU - Naresh, Alpana
AU - Kitabayashi, Issay
AU - Cleary, Michael L.
PY - 2010/2/17
Y1 - 2010/2/17
N2 - AF4 and ENL family proteins are frequently fused with MLL, and they comprise a higher order complex (designated AEP) containing the P-TEFb transcription elongation factor. Here, we show that AEP is normally recruited to MLL-target chromatin to facilitate transcription. In contrast, MLL oncoproteins fused with AEP components constitutively form MLL/AEP hybrid complexes to cause sustained target gene expression, which leads to transformation of hematopoietic progenitors. Furthermore, MLL-AF6, an MLL fusion with a cytoplasmic protein, does not form such hybrid complexes, but nevertheless constitutively recruits AEP to target chromatin via unknown alternative mechanisms. Thus, AEP recruitment is an integral part of both physiological and pathological MLL-dependent transcriptional pathways. Bypass of its normal recruitment mechanisms is the strategy most frequently used by MLL oncoproteins.
AB - AF4 and ENL family proteins are frequently fused with MLL, and they comprise a higher order complex (designated AEP) containing the P-TEFb transcription elongation factor. Here, we show that AEP is normally recruited to MLL-target chromatin to facilitate transcription. In contrast, MLL oncoproteins fused with AEP components constitutively form MLL/AEP hybrid complexes to cause sustained target gene expression, which leads to transformation of hematopoietic progenitors. Furthermore, MLL-AF6, an MLL fusion with a cytoplasmic protein, does not form such hybrid complexes, but nevertheless constitutively recruits AEP to target chromatin via unknown alternative mechanisms. Thus, AEP recruitment is an integral part of both physiological and pathological MLL-dependent transcriptional pathways. Bypass of its normal recruitment mechanisms is the strategy most frequently used by MLL oncoproteins.
UR - http://www.scopus.com/inward/record.url?scp=76349118080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76349118080&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2009.12.040
DO - 10.1016/j.ccr.2009.12.040
M3 - Article
C2 - 20153263
AN - SCOPUS:76349118080
SN - 1535-6108
VL - 17
SP - 198
EP - 212
JO - Cancer Cell
JF - Cancer Cell
IS - 2
ER -